Related Experiment Video
Updated: May 3, 2026

Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
Published on: May 24, 2017
Effect of nicotine replacement therapy on quitting by young adults in a trial comparing cessation services
David B Buller1, Abigail Halperin, Herbert H Severson
1Klein Buendel, Inc, Golden, Colorado (Drs Buller and Bettinghaus); Department of Family Medicine, University of Washington, Seattle (Dr Halperin); Oregon Research Institute, Eugene (Dr Severson); Cancer Council Victoria, Carlton South, Victoria, Australia (Dr Borland); School of Communication, Ohio State University, Columbus (Dr Slater); National Jewish Health, Denver, Colorado (Dr Tinkelman); School of Public Health, University of Alabama at Birmingham (Dr Cutter); and Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico, Albuquerque (Dr Woodall).
Context:
Young adult smokers have the highest smoking prevalence among all US age groups but are least likely to use evidence-based cessation counseling or medication to quit.
Objective:
Use and effectiveness of nicotine patch were explored in a randomized trial evaluating smoking cessation interventions with this population.
Participants:
Smokers aged 18 to 30 (n = 3094) were recruited through online and off-line methods and from telephone quit lines and analyzed.
Design:
Smokers were enrolled in a pretest-posttest trial, and randomized to 1 of 3 cessation services.
Setting:
Trial delivering counseling services by self-help booklet, telephone quit lines, or online expert system in the 48 continental United States.
Intervention:
Smokers could request a free 2-week course of nicotine replacement therapy (NRT) patches from the project.
Main Outcome Measure:
Follow-up surveys at 12 and 26 weeks assessed smoking abstinence, use of NRT, counseling, and other cessation medications, and smoking-related variables.
Results:
Overall, 69.0% of smokers reported using NRT (M = 3.2 weeks) at 12 weeks and 74.8% (M = 3.3 weeks) at 26 weeks. More smokers who were sent the free nicotine patches (n = 1695; 54.8%) reported using NRT than those who did not receive them (12 weeks: 84.3% vs 41.9%, P < .001; 26 weeks: 87.6% vs 51.1%, P < .001). The use of NRT was associated with greater smoking abstinence at 12 weeks (P < .001) and 26 weeks (P < .05), especially if used for more than 2 weeks (P < .001). Smokers assigned to a self-help booklet or cessation Web site and heavier smokers were most likely to use NRT (P < .05), whereas those reporting marijuana use and binge drinking used NRT less (P < .05).
Conclusions:
Many young adults were willing to try NRT, and it appeared to help them quit in the context of community-based cessation services. Strategies should be developed to make NRT available to this age group and support them in using it to prevent lifelong smoking.
More Related Videos
06:39Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements
Published on: August 28, 2017
09:25Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Drug Dependence
CNS Depressants: Alcohol and Nicotine
Clinical Trials: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients